ICU Admission, Oxygen Use Predict Outcomes in Patients With Cancer and COVID-19
Markus Joerger, MD, discussed the outcomes and prognostic factors of patients with cancer won contract COVID-19 in an interview with Targeted Oncology.
Related Articles
LITESPARK-005: Belzutifan in Previously Treated Advanced Clear Cell RCC
Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.
FDA Clears IND of BTX-9341 in HR+/HER2- Breast Cancer
With the clearance of an investigational new drug application for BTX-9341 from the FDA, a phase 1 trial will evaluate the agent in HR-positive/HER2-negative breast…
Setanaxib With Pembrolizumab Boosts Survival in Recurrent/Metastatic SCCHN
Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.
Quality of Life + Clinical Monitoring Outside the Transplant Center
Yi-Bin Chen, MD, proposes a strategy to enhance patients’ quality of life by utilizing virtual monitoring as an alternative to requiring patients to travel to…
About the Phase 3 SunRISe-5 Study of TAR-200
Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder cancer and unmet needs in this…
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
During a Case-Based Roundtable® event, Ruth M. O’Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a…
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease…
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
During a Case-Based Roundtable® event, Ruth M. O’Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a…
FDA Oks ColoSense, a Stool Test for Early Colorectal Cancer Detection
The FDA has approved ColoSense, a stool screening test with 93% accuracy for colon cancer in average-risk adults over the age of 45. This noninvasive…
FDA to Consider Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.